Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
2UrbanGirls on MSN
The easiest and fastest way to go viral (anyone can do it)
Discover the proven viral clip translation method that's helping creators explode their growth. Learn exactly how to f ...
(MENAFN- GlobeNewsWire - Nasdaq) [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Viral Vaccine Cell Culture Media ...
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of ...
Researchers from Indian Institute of Science Education and Research (IISER) Mohali have discovered that unique antibodies from camels may help neutralise the dengue virus. Scientists say these tiny "n ...
In a phase 3 clinical trial, the tetravalent dengue vaccine, developed by the Butantan Institute in São Paulo, Brazil, was 80.5% effective against severe dengue cases with warning signs over a ...
Christopher H. Contag explores how tissue regeneration involves organized interactions beyond just cell replacement, highlighting two emerging technologies ...
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...
The increasing problem of plagiarism in the fashion industry raises pressing questions about novelty, ownership and survival in the digital age, despite laws in place ...
Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous ...
Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results